Literature DB >> 19391667

Perivascular epithelioid cell tumor.

Henry B Armah1, Anil V Parwani.   

Abstract

Perivascular epithelioid cell tumors are mesenchymal neoplasms defined by the presence of histologically and immunohistochemically distinctive perivascular epithelioid cells. The perivascular epithelioid cell has no known normal tissue counterpart and coexpresses myoid and melanocytic markers. This tumor family shows marked female predominance and includes angiomyolipoma, clear cell sugar tumor, lymphangioleiomyomatosis, and a group of rare, morphologically and immunophenotypically similar tumors arising at a variety of visceral and soft tissue sites. This latter subset has been collectively termed perivascular epithelioid cell tumors-not otherwise specified. They are usually composed of epithelioid, but occasionally spindled, cells with clear to granular eosinophilic cytoplasm and focal perivascular accentuation. The mainstay of treatment is wide excision. Although most cases are benign, a subset behaves in a malignant fashion. Since few malignant cases have been reported, firm criteria for malignancy have yet to be established. This review focuses on the perivascular epithelioid cell tumors-not otherwise specified subset.

Entities:  

Mesh:

Year:  2009        PMID: 19391667     DOI: 10.5858/133.4.648

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  42 in total

Review 1.  Renal angiomyolipoma without visible fat: Can we make the diagnosis using CT and MRI?

Authors:  Robert S Lim; Trevor A Flood; Matthew D F McInnes; Luke T Lavallee; Nicola Schieda
Journal:  Eur Radiol       Date:  2017-08-04       Impact factor: 5.315

2.  An Unusual Combination of Biliary Cystadenoma and Renal Angiomyolipoma- A Case Report.

Authors:  Sheeja S; Renu Thambi; Sylvia Syriac; Anil Kumar
Journal:  J Clin Diagn Res       Date:  2016-05-01

3.  Primary retroperitoneal perivascular epithelioid cell neoplasm: A case report.

Authors:  Wenjie Liang; Chang Xu; Feng Chen
Journal:  Oncol Lett       Date:  2015-05-14       Impact factor: 2.967

4.  Malignant perivascular epithelioid cell tumor (PEComa) of cervix with TFE3 gene rearrangement: a case report.

Authors:  Feifei Liu; Renya Zhang; Zi-Yu Wang; Qiuyuan Xia; Qin Shen; Shanshan Shi; Pin Tu; Qunli Shi; Xiaojun Zhou; Qiu Rao
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

5.  Uncommon of the uncommon: malignant perivascular epithelioid cell tumor of the lung.

Authors:  Hyun-Ju Lim; Ho Yun Lee; Joungho Han; Yong Soo Choi; Kyung Soo Lee
Journal:  Korean J Radiol       Date:  2013-07-17       Impact factor: 3.500

6.  Perivascular epithelioid cell tumors (PEComas) harboring TFE3 gene rearrangements lack the TSC2 alterations characteristic of conventional PEComas: further evidence for a biological distinction.

Authors:  Izabela Malinowska; David J Kwiatkowski; Sharon Weiss; Guido Martignoni; George Netto; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2012-05       Impact factor: 6.394

7.  Premelanosome-negative inflammatory angiomyolipoma of liver with expression of cathepsin K and TFE3.

Authors:  Ke Sun; Ming Zhao; Hongtian Yao; Lijun Wang; Jianfeng Wei
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

Review 8.  Perivascular epithelioid cell tumor in the duodenum: challenge in differential diagnosis.

Authors:  Zehong Chen; Huijuan Shi; Jianjun Peng; Yujie Yuan; Jianhui Chen; Wu Song
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

9.  Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa.

Authors:  Fang Gao; Chengsuo Huang; Yiping Zhang; Ruirui Sun; Yujie Zhang; Huijun Wang; Shu Zhang
Journal:  Cancer Biol Ther       Date:  2016-03-30       Impact factor: 4.742

10.  Smooth muscles and stem cells of embryonic guts express KIT, PDGFRRA, CD34 and many other stem cell antigens: suggestion that GIST arise from smooth muscles and gut stem cells.

Authors:  Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2013-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.